Fundraising FoxLion Biotechnologies
NASDAQ: IOVANew York, US · Delaware corporation · 1 known investors
Find your way into Lion Biotechnologies
Sign up to see every warm intro you have to Lion Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lion Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lion Biotechnologies develops and commercializes TIL (tumor infiltrating lymphocyte) cell therapies, individualized immunotherapies manufactured from patient T cells to treat solid tumor cancers, with its lead product Amtagvi approved for previously treated advanced melanoma and a pipeline of combination therapies and monotherapies for additional cancer types.
Founders & leadership
Board
Investors · 1
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$100M disclosed across 1 of 2 rounds · 2013–2016
▶$100MraisedJun 2016 · 24 investors · BiotechnologyRule 506(b)
- Molly C. HendersonExecutive Officer
- Michael T. LotzeExecutive Officer
- Merrill McPeakDirector
- Steven A. FischkoffExecutive Officer
- Sanford J, HillsbergDirector
- Jay VenkatesanDirector
- Wayne RothbaumDirector
- Maria FardisExecutive Officer, Director
- Ryan MaynardDirector
- Offering amount
- $100M
- Amount sold
- $100M
- Sales commissions
- $4M
- Placement agents
- Piper Jaffray & Co., Jefferies LLC
- First sale
- Jun 2016
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Lion Biotechnologies do?
- Lion Biotechnologies develops and commercializes TIL (tumor infiltrating lymphocyte) cell therapies, individualized immunotherapies manufactured from patient T cells to treat solid tumor cancers, with its lead product Amtagvi approved for previously treated advanced melanoma and a pipeline of combination therapies and monotherapies for additional cancer types.
- Who are Lion Biotechnologies's investors?
- Lion Biotechnologies's investors include BlackRock.
- How much funding has Lion Biotechnologies raised?
- Lion Biotechnologies has disclosed $100M raised across 1 of its 2 known rounds.
- Where is Lion Biotechnologies headquartered?
- Lion Biotechnologies is headquartered in New York, US.